Welcome to our dedicated page for Clene SEC filings (Ticker: CLNNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Clene's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Clene's regulatory disclosures and financial reporting.
Clene Inc. insider associated entity sells shares in two open-market transactions. An entity linked to ten percent owner Ugwumba Chidozie, identified as SymBiosis II, LLC, sold 4,318 shares of Clene common stock at $6.12 per share on April 20, 2026, followed by 61,345 shares at $6.14 per share on April 21, 2026. After the April 21 sale, the filing reports 297,066 Clene shares indirectly held by this entity.
Clene Inc. insider associated entity sells shares in two open-market transactions. An entity linked to ten percent owner Ugwumba Chidozie, identified as SymBiosis II, LLC, sold 4,318 shares of Clene common stock at $6.12 per share on April 20, 2026, followed by 61,345 shares at $6.14 per share on April 21, 2026. After the April 21 sale, the filing reports 297,066 Clene shares indirectly held by this entity.
Clene Inc. ten percent owner Ugwumba Chidozie, through SymBiosis II, LLC, reported open-market sales of Clene common stock over three days. SymBiosis II, LLC sold 6,374 shares at $6.48 on April 15, 7,748 shares at $6.40 on April 16, and 25,040 shares at $6.43 on April 17, leaving 362,729 shares of indirect ownership after the latest transaction.
Clene Inc. ten percent owner Ugwumba Chidozie, through SymBiosis II, LLC, reported open-market sales of Clene common stock over three days. SymBiosis II, LLC sold 6,374 shares at $6.48 on April 15, 7,748 shares at $6.40 on April 16, and 25,040 shares at $6.43 on April 17, leaving 362,729 shares of indirect ownership after the latest transaction.
CLNN filed a Form 144 notice reporting proposed sales of Common Stock, listing an entry of 401,891 shares under “Securities To Be Sold” (dated 09/30/2024) and multiple completed open-market sales by Symbiosis II LLC with trade dates and per-trade share counts and proceeds in 2026. The filing lists open-market purchase / resale activity and indicates cash transactions.
CLNN filed a Form 144 notice reporting proposed sales of Common Stock, listing an entry of 401,891 shares under “Securities To Be Sold” (dated 09/30/2024) and multiple completed open-market sales by Symbiosis II LLC with trade dates and per-trade share counts and proceeds in 2026. The filing lists open-market purchase / resale activity and indicates cash transactions.
Clene Inc. is asking stockholders to vote at its 2026 Annual Meeting on May 21, 2026, in Salt Lake City. Holders of common stock at the March 25, 2026 record date can vote online, by phone, mail, or in person, with one vote per share.
Stockholders will elect three Class III directors to terms ending in 2029, ratify Deloitte as independent auditor for 2026, and cast an advisory vote on executive pay. A key item seeks to amend the Amended 2020 Stock Plan to add 1,000,000 shares, raising the share reserve from 3,220,000 to 4,220,000.
As of March 25, 2026, Clene had 11,778,307 common shares outstanding, 3,006,484 options outstanding under the plan, and 197,177 shares remaining available for grants. The company discloses a three-year average equity burn rate of 9.99% and estimates fully‑diluted overhang of 22.0%, which would rise to 26.8% if the amendment is approved.
Clene Inc. is asking stockholders to vote at its 2026 Annual Meeting on May 21, 2026, in Salt Lake City. Holders of common stock at the March 25, 2026 record date can vote online, by phone, mail, or in person, with one vote per share.
Stockholders will elect three Class III directors to terms ending in 2029, ratify Deloitte as independent auditor for 2026, and cast an advisory vote on executive pay. A key item seeks to amend the Amended 2020 Stock Plan to add 1,000,000 shares, raising the share reserve from 3,220,000 to 4,220,000.
As of March 25, 2026, Clene had 11,778,307 common shares outstanding, 3,006,484 options outstanding under the plan, and 197,177 shares remaining available for grants. The company discloses a three-year average equity burn rate of 9.99% and estimates fully‑diluted overhang of 22.0%, which would rise to 26.8% if the amendment is approved.
Clene Inc. insider filing shows an indirect share sale by a large holder. On April 2, 2026, SymBiosis II, LLC, an entity associated with ten percent owner Ugwumba Chidozie, completed an open-market sale of 24,925 shares of Clene common stock at $4.81 per share. Following this transaction, the entity continued to hold 401,891 shares of common stock indirectly, indicating the sale represented only a portion of its overall position.
Clene Inc. insider filing shows an indirect share sale by a large holder. On April 2, 2026, SymBiosis II, LLC, an entity associated with ten percent owner Ugwumba Chidozie, completed an open-market sale of 24,925 shares of Clene common stock at $4.81 per share. Following this transaction, the entity continued to hold 401,891 shares of common stock indirectly, indicating the sale represented only a portion of its overall position.
Clene Inc. ten percent owner associated entity sells shares. An entity linked to Ugwumba Chidozie, SymBiosis II, LLC, completed an open-market sale of 4,278 shares of Clene Inc. common stock at $4.97 per share. After this transaction, the entity still holds 426,816 shares indirectly.
Clene Inc. ten percent owner associated entity sells shares. An entity linked to Ugwumba Chidozie, SymBiosis II, LLC, completed an open-market sale of 4,278 shares of Clene Inc. common stock at $4.97 per share. After this transaction, the entity still holds 426,816 shares indirectly.
CLNN reports multiple proposed and executed sales of Common Stock by Symbiosis II LLC as disclosed on Form 144. The filing lists numerous open-market dispositions on dated entries, including 31,297 shares on 03/31/2026 for $152,316.52 and 32,705 shares on 01/12/2026 for $179,867.17. Transactions are shown across January–March 2026 with individual trade sizes and cash amounts reported per line item.
CLNN reports multiple proposed and executed sales of Common Stock by Symbiosis II LLC as disclosed on Form 144. The filing lists numerous open-market dispositions on dated entries, including 31,297 shares on 03/31/2026 for $152,316.52 and 32,705 shares on 01/12/2026 for $179,867.17. Transactions are shown across January–March 2026 with individual trade sizes and cash amounts reported per line item.
CLNN affiliate submitted a Form 144 notice to sell 477,000 shares of Common Stock.
The filing lists multiple recent open‑market dispositions by Symbiosis II LLC from 12/22/2025 through 02/03/2026, with per‑trade share counts and gross proceeds reported for each trade.
CLNN affiliate submitted a Form 144 notice to sell 477,000 shares of Common Stock.
The filing lists multiple recent open‑market dispositions by Symbiosis II LLC from 12/22/2025 through 02/03/2026, with per‑trade share counts and gross proceeds reported for each trade.
Clene Inc. is a clinical-stage pharmaceutical company focused on clean-surfaced nanocrystal (CSN) therapeutics targeting neurodegenerative diseases such as ALS, multiple sclerosis, and Parkinson’s disease. Its lead asset, CNM-Au8, is an orally delivered gold nanocrystal suspension designed to boost cellular energy and reduce oxidative stress.
The company reports extensive preclinical and Phase 1–2 data suggesting neuroprotective, remyelinating, and biomarker effects, including NAD+/ATP increases and reduced neurofilament light chain in ALS. Clene is pursuing an accelerated approval pathway for CNM-Au8 in ALS, aiming to submit an NDA by June 2026 and planning a Phase 3 RESTORE-ALS trial as a confirmatory study, subject to funding.
Clene Inc. is a clinical-stage pharmaceutical company focused on clean-surfaced nanocrystal (CSN) therapeutics targeting neurodegenerative diseases such as ALS, multiple sclerosis, and Parkinson’s disease. Its lead asset, CNM-Au8, is an orally delivered gold nanocrystal suspension designed to boost cellular energy and reduce oxidative stress.
The company reports extensive preclinical and Phase 1–2 data suggesting neuroprotective, remyelinating, and biomarker effects, including NAD+/ATP increases and reduced neurofilament light chain in ALS. Clene is pursuing an accelerated approval pathway for CNM-Au8 in ALS, aiming to submit an NDA by June 2026 and planning a Phase 3 RESTORE-ALS trial as a confirmatory study, subject to funding.
Clene Inc. filed an 8-K after issuing a stockholder letter that maps out 2026 milestones for its ALS drug candidate CNM-Au8 and its funding plan. The company completed an oversubscribed registered direct offering of over $28 million, with an initial tranche of over $6 million expected to fund operations into the fourth quarter of 2026. Two additional tranches totaling over $22 million are structured around potential FDA NDA acceptance and approval milestones and are expected to support operations into 2027. Clene plans an in-person Type C FDA meeting by the end of the first quarter of 2026, aims to submit a New Drug Application for CNM-Au8 via an accelerated pathway in the second quarter of 2026, and sees potential for FDA acceptance, a PDUFA decision date, and possible 2027 commercial launch. The letter highlights survival and biomarker data in ALS, a favorable safety profile over more than 1,000 patient years, and plans to start the confirmatory Phase 3 RESTORE-ALS trial later in 2026.
Clene Inc. filed an 8-K after issuing a stockholder letter that maps out 2026 milestones for its ALS drug candidate CNM-Au8 and its funding plan. The company completed an oversubscribed registered direct offering of over $28 million, with an initial tranche of over $6 million expected to fund operations into the fourth quarter of 2026. Two additional tranches totaling over $22 million are structured around potential FDA NDA acceptance and approval milestones and are expected to support operations into 2027. Clene plans an in-person Type C FDA meeting by the end of the first quarter of 2026, aims to submit a New Drug Application for CNM-Au8 via an accelerated pathway in the second quarter of 2026, and sees potential for FDA acceptance, a PDUFA decision date, and possible 2027 commercial launch. The letter highlights survival and biomarker data in ALS, a favorable safety profile over more than 1,000 patient years, and plans to start the confirmatory Phase 3 RESTORE-ALS trial later in 2026.